Captozyme, a Gainesville-based biotechnology company, is among 50 statewide companies expected to see significant growth over the next several years. Captozyme was selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association with the Edward Lowe Foundation.
Nephure™, an oxalate degrading enzyme manufactured by Captozyme, has received self-affirmed GRAS (Generally Recognized as Safe) notification by an independent panel of experts through scientific procedure following stringent US Food and Drug Administration (FDA) safety criteria. The independent panel evaluated a comprehensive dossier of characterization data and safety studies and concluded that Nephure is safe for use as a food ingredient.
Upon graduating from the University of Florida’s Innovation Hub, local biotechnology company, Captozyme Inc., recently acquired a newly constructed facility to house their new headquarters at 1622 NW 55th Place. The company plans to consolidate all operations there during the coming months, and is proud to be part of the developing biotechnology scene of Gainesville.
Captozyme is pleased to announce that they have officially graduated from the University of Florida's Innovation Hub. In the fall of 2014 Captozyme found its home at the university's incubator for start-up companies in the technology and biotechnology fields. Now, a little over 2 years later, Captozyme graduates with 14 employees and a new office and lab space in north Gainesville.
Captozyme was recently honored in being one of the 20 companies chosen to present at the Florida Venture Forum out of more than 100 applicants. The Florida Venture Forum's mission is to connect emerging Florida-based companies with resources and capital nationwide.